Reviewer's report

Title: Use of Immunohistochemical Markers can Refine Prognosis in Triple Negative Breast Cancer

Version: 3 Date: 27 June 2007

Reviewer: Dan H Moore

Reviewer's report:

General
The authors have responded appropriately to my Major Compulsory Revisions. However, their response does not deal with the issue of drop-outs between 3 and 10 years of follow-up. (This was my fault since I did not list it as a Major Compulsory Revision.)

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)
1. What happens when you rerun the analysis excluding patients who dropped out (i.e. were not followed for 10 years)? This does not mean excluding those who died between 3 and 10 yrs. My concern is that patients with a particular value for a biomarker could be at higher risk of dropping out (not dying, but being lost to followup) between 3 and 10 years so that their findings could be confounded by different drop-out rates for different marker values.

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
None

Discretionary Revisions (which the author can choose to ignore)
None

What next?: Unable to decide on acceptance or rejection until the authors have responded to the major compulsory revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that I have no competing interests.